Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

863.39 +30.24 (+3.63%)

Streaming Delayed Price Updated: 2:42 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis

November 16, 2023

From argenx SE

Via GlobeNewswire

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

November 15, 2023

Via Benzinga

Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth ↗

November 06, 2023

Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth.

Via InvestorPlace

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today ↗

November 01, 2023

Via Benzinga

Earnings Outlook For argenx ↗

October 30, 2023

Via Benzinga

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

November 01, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

November 01, 2023

From argenx SE

Via GlobeNewswire

Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses ↗

October 31, 2023

The company sells Vyvgart, a treatment for generalized myasthenia gravis.

Via Investor's Business Daily

Topics Earnings

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

October 31, 2023

From argenx SE

Via GlobeNewswire

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023

From argenx SE

Via GlobeNewswire

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 19, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 03, 2023

Via Benzinga

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗

September 29, 2023

But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.

Via Investor's Business Daily

What's Going On Pfizer's Subsidiary Biohaven Stock? ↗

September 27, 2023

Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an

Via Benzinga

Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗

September 27, 2023

The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.

Via Investor's Business Daily

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗

September 27, 2023

Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.

Via Investor's Business Daily

The Latest Analyst Ratings for argenx ↗

September 18, 2023

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

What 20 Analyst Ratings Have To Say About argenx ↗

August 31, 2023

Via Benzinga

Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up ↗

September 26, 2023

Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.

Via Investor's Business Daily

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

September 21, 2023

From argenx SE

Via GlobeNewswire

This New S&P 500 Entrant Leads 5 Stocks Near Buy Points ↗

September 16, 2023

These stocks could lead if the market rallies.

Via Investor's Business Daily

Topics Stocks

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗

August 30, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

August 10, 2023

Via Benzinga

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

September 15, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

August 30, 2023

From argenx SE

Via GlobeNewswire

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market ↗

August 19, 2023

Arista Networks and Dutch biotech Argenx lead this weekend's watch list.

Via Investor's Business Daily

Topics Artificial Intelligence

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.